AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.
The government has confirmed that boys in England will be vaccinated against the human papilloma virus in line with recent recommendations from the Joint Committee on Vaccination and Immunisation (JCVI).
US regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a treatment for patients experiencing a sudden worsening of chronic obstructive pulmonary disorder (COPD).
Shares in UK-based clinical-stage biopharm PureTech Health have been given a boost by news that Roche has signed up to advance its exosome platform technology in a deal potentially worth more than $1 billion.
Clinicians in the UK should have the option to prescribe cannabis-derived medicinal products where appropriate, drug experts have concluded, paving the way for laws prohibiting their use to be relaxed.
Allergan, Molecular Partners’ abicipar has shown non-inferiority to Novartis’ Lucentis but with fewer injections in late-stage trials involving patients with neovascular age-related macular degeneration.